A Baltimore vaccine developer that takes its name from the Latin phrase for "to advance or improve" will be doing just that to its vaccine innovation center near Tarrytown, NY.

During the process, Profectus BioSciences’ center will roughly triple in size as part of an expansion fueled by its acquisition of technologies from Wyeth and the University of Maryland School of Medicine's Institute of Human Virology, as well as plans to launch six Phase 1 studies into the safety and effectiveness of its HIV prime-boost therapeutic vaccine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.